In this episode, Specialty Primary Care Physician Dr Peter Lin and host Dr David Lim takes GPs on a tour from ACE2 to cytokine storms, showing how the virus can quietly dismantle multiple organ systems and what that means for your high-risk patients this winter:

• Why COVID-19 is more than a respiratory virus
• How ACE2 disruption drives organ damage
• The renin–angiotensin system and long-term COVID complications
• Why COVID differs clinically from influenza and RSV
• Why older adults and those with comorbidities are at high risk of severe disease
• Practical strategies for testing, and the role of vaccines and antivirals

Expert: Dr Peter Lin, Specialty Primary Care Physician

Host: Dr David Lim, GP & Medical Educator

Total time: 33 mins

This educational activity is developed by Healthed with funding provided by Pfizer. Any of the views shared are those of the speakers and not endorsed by Pfizer.

Most frequent adverse reactions to PAXLOVID include dysgeusia and diarrhoea.

Before prescribing, please review full product information for PAXLOVID (nirmatrelvir/ritonavir) available here.

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Alternatively, any adverse events which are experienced with PAXLOVID® can be reported to Pfizer on 1800 675 229 or by email to AUS.AEReporting@pfizer.com

Warning: Nirmatrelvir with ritonavir has significant drug-drug interactions. Prescribers and dispensers should carefully review a patient’s concomitant medications.

PBS Information: PAXLOVID is Authority Required (STREAMLINED). Category: GENERAL – General Schedule (Code GE). For verified SARS-CoV-2 infection. Treatment must be initiated within 5 days of symptom onset. Refer to PBS Schedule for full authority information.

Most frequent adverse reactions to COMIRNATY include injection site pain, fatigue, headache, myalgia, chills and arthralgia. There have been very rare reports of myocarditis and pericarditis.

Before prescribing, please review full product information for COMIRNATY (mRNA COVID-19 vaccine) available here.

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

PBS Information: COMIRNATY is not listed on the PBS and is not listed on the NIP.

This podcast is sponsored by Pfizer Australia Pty Ltd, Sydney Australia. Date recorded: March 2026.

© 2026. All rights reserved. Pfizer Australia. Sydney, Australia. ww.pfizer.com.au.
Pfizer Medical Information: 1800 675 229. PP-C1D-AUS-0689. PAX-004588-04. 05/26.